Home
GSC Biological and Pharmaceutical Sciences
Peer-reviewed Journal | Impact factor 8.1 | ISSN: 2581-3250 | CAS Source Indexed | Crossref DOI

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

Research and review articles are invited for publication in September 2026 - Vol. 36, Issue 3 

🌟 GSC Biological and Pharmaceutical Sciences (GSCBPS) 🌟

Low Publication Charges | Fast Editorial Processing | Crossref DOI Linking | Transparent Peer-Review Process

Publishing quality research in Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare and Allied Life Sciences.

e-ISSN: 2581-3250 | Impact Factor: 8.1 | Established: 2017 | Charges: USD 35 / INR 2100

📄 Submit Manuscript 👉 Author Guidelines 📚 Published Articles 

Therapeutic drug monitoring of imatinib in patients with chronic myeloid leukaemia: Experience from Oran HUE

Breadcrumb

  • Home
  • Therapeutic Drug Monitoring of Imatinib In Patients With Chronic Myeloid Leukaemia: Experience From Oran HUE
  • Therapeutic drug monitoring of imatinib in patients with chronic myeloid leukaemia: Experience from Oran HUE

Hamza BENBACHIR 1, *, Hichem NAAS 2, Hichem BOUGUEDRA 1, Souad GENDOUZ 3, Badra ENTA SOLTAN 4, Hassan CHADOU 1, Amina AMIAR 1, Nabil YAFOUR 4 and Houari TOUMI 1

1 Pharmacovigilance department, University Hospital Establishment of Oran, Algeria.
2 Mohamed Lamine Debaghine University Hospital Center, Algiers, Algeria.
3 Tlemcen Faculty of Medicine, Abu Bakr Belkaid University, Tlemcen, Algeria.
4 Hematology department, University Hospital Establishment of Oran, Algeria.
Research Article
GSC Biological and Pharmaceutical Sciences, 2023, 25(03), 201–209.
Article DOI: 10.30574/gscbps.2023.25.3.0533
DOI url: https://doi.org/10.30574/gscbps.2023.25.3.0533
Received on 15 November 2023; revised on 25 December 2023; accepted on 27 December 2023
Imatinib, a first-line treatment for chronic myelogenous leukemia, presents significant interindividual pharmacokinetic variability. The correlation between the plasma exposure of Imatinib and its pharmacological effects makes this drug a good candidate for pharmacological therapeutic monitoring in addition to the usual monitoring tests. We introduced monitoring of Imatinib in 27 patients suffering from chronic myelogenous leukemia. According to the dosage results, dosage adaptation recommendations were proposed to clinicians in patients outside the targeted therapeutic range. The goal was to achieve an optimal response to Imatinib, prevent its adverse effects and improve adherence to treatment.
Imatinib; Therapeutic drug monitoring; Chronic myelogenous leukemia; Dosage adaptation; Major molecular response
https://gscbps.gsconlinepress.com/sites/default/files/fulltext_pdf/GSCBPS-2023-…

Preview Article PDF

Hamza BENBACHIR, Hichem NAAS, Hichem BOUGUEDRA, Souad GENDOUZ, Badra ENTA SOLTAN, Hassan CHADOU, Amina AMIAR, Nabil YAFOUR and Houari TOUMI. Therapeutic drug monitoring of imatinib in patients with chronic myeloid leukaemia: Experience from Oran HUE. GSC Biological and Pharmaceutical Sciences, 2023, 25(3), 201-209. Article DOI: https://doi.org/10.30574/gscbps.2023.25.3.0533


📝 Copyright, Licensing and Permissions: © Copyright Author(s). This article is published under the 🌐 Creative Commons Attribution 4.0 International License (CC BY 4.0) , which permits unrestricted use, distribution, adaptation, and reproduction in any medium, provided the original author(s) and source are properly credited, a link to the license is provided, and any changes made are indicated.


⚠️ Disclaimer: The statements, opinions, interpretations, and data presented in this publication are solely those of the individual author(s). GSC Biological and Pharmaceutical Sciences (GSCBPS), the editors, reviewers, editorial board, and publisher disclaim responsibility for any errors, omissions, or consequences arising from the use of the information contained in this article.


🏆 Get Publication Certificate 📄 Download Letter of Acceptance 🔗 Verify Crossref DOI 📘 View Issue Cover Page 👨‍🔬 Editorial Board 📑 Table of Contents 

🚀 Publish Your Research in International Peer Reviewed Open Access Journal - GSC Biological and Pharmaceutical Sciences (GSCBPS)

Submit your manuscripts from Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare, Biotechnology and Allied Life Sciences etc.

🌍 International Journal   |   👨‍🔬 Transparent Peer Review Process   |   🌐 Open Access Publishing   |   🔗 Crossref DOI 
⚡ Fast Editorial Processing   |   💰 Low Publication Charges

📝 Submit Your Manuscript 📘 Author Guidelines 💰 Publication Charges 

✅ No Submission Fee •  📜 Free Publication Certificate • 🌍 Global Visibility

⭐ Popular Pages


  • 🌍 International Journal
  • 🌐 Open Access Journal
  • 👨‍⚖️ Peer-Reviewed Journal
  • 💰 Low APC Journal
  • 🚀 Fast Publication Journal
  • ⚡ Fast-Track Peer-Review
  • 🔗 Crossref DOI Journal
  • 📖 Refereed Journal
  • 📈 High Impact Journal
  • 🧬 International Biology Journal
  • 💊 International Pharmacy Journal
  • 📝 Publish Research Paper

✍️ Author Resources


  • 📝 Publish Research Paper
  • 📖 Author Guidelines
  • 🎯 Aims and Scope
  • 💳 Article Processing Charges
  • 📤 Submit Manuscript
  • 📄 Cover Letter
  • ✍️ Author Declaration Form
  • 📄Track Manuscript Status
  • 📜 Get Publication Certificate
  • 📚 Journal Past Issue Archive
  • 🔎 Journal Indexing

⚖️ Journal Policies


  • ⚖️ Publication Ethics
  • 🛡️ Plagiarism Policy
  • 👨‍🔬 Peer Review Policy
  • 👨‍⚖️ Peer Review Process
  • 📖 Open Access Publishing
  • 📜 Copyright & Licensing
  • 🔗Author Self-Archiving Policy
  • 👥 Authorship Policy
  • 📊 Data Sharing Policy
  • 🤖 AI Usage Policy

Copyright © 2026 GSC Biological and Pharmaceutical Sciences - All rights reserved

Developed & Designed by VS Infosolution